TMCnet News
Phillips-Medisize Unveils Aria Smart Autoinjector Platform to Drive Innovation and Sustainability in Digital Drug DeliveryHUDSON, Wis., May 26, 2021 /PRNewswire/ -- Phillips-Medisize, a Molex company and leader in drug delivery, diagnostic and MedTech devices, today unveiled the Aria Smart Autoinjector platform to unlock innovation, differentiation and sustainability in the digital drug-delivery device market. This latest advancement introduces a small and simple, smart injection device featuring a reusable electronic drive unit and single-use, disposable cassettes to elevate patient care while reducing environmental impact. "With the Aria Smart Autoinjector, we are disrupting this sector with a game-changing platform that brings the right functionality to market in the right form factor at the right time," said Kevin Deane, VP, Innovation at Phillips-Medisize. "Our goal from the outset has been to develop an injector that patients love, combining the simplicity of current disposable devices with the superior performance, sustainability and connectivity possible through an electronic, reusable device." According to an April 2021 survey commissioned by Molex and Phillips-Medisize on "Digital Health and the Future of Pharma," digitized drug delivery is on the rise. More than half of pharmaceutical professionals polled expect digital drug delivery to improve patient outcomes for many types of drug treatments. Nearly everyone reported adoption challeges, however, with usability and sustainability among the obstacles reported most frequently by participants from companies currently marketing one or more therapies. Extending Patient Experience and Ease of Use Key findings from a recent Phillips-Medisize user study reinforce Aria's ease of use, as 100% of experienced and novice users successfully completed self-injection without training. Moreover, no users lifted the device too early during the injection while unanimously confirming the importance of sustainability. Reducing Environmental Impact Connecting Real-Time Patient Data Providing Customized, Differentiated Performance at an Attractive Cost The Aria Smart Autoinjector platform is available in a basic model with a simple user interface for standard injection sequences and an advanced model with a screen-based Graphical User Interface (GUI) to offer more user interaction for complex injections. Phillips-Medisize is collaborating with pharma customers to run comparative user studies and feasibility assessments, as well as full development programs for combination products. The device can support drug portfolios of innovator companies as well as for biosimilars and generics, where an attractive cost-per-injection is a critical consideration. Phillips-Medisize and Molex About Molex View original content to download multimedia:http://www.prnewswire.com/news-releases/phillips-medisize-unveils-aria-smart-autoinjector-platform-to-drive-innovation-and-sustainability-in-digital-drug-delivery-301299695.html SOURCE Molex Incorporated |